The pharmaceutical ingredients manufacturer will conduct three rounds of job cuts starting in May and continuing through 2026 ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

“Due to significant reductions in demand for these products, the company has decided to cease operations at the plant,” the ...

Drugmakers are urging the Trump administration and European Union officials to exclude medical goods from expanding tariff ...

Merck & Co. Inc. closed 29.59% below its 52-week high of $134.63, which the company reached on June 25th.

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free ...

The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...

Merck KGa A officials say that, ultimately, the SMARTfacturing transformation benefits its customers, patients, and the ...

We recently published a list of 12 Incredibly Cheap Dividend Stocks to Buy Now. In this article, we are going to take a look ...

On March 13, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed a five-year patent term extension (“PTE”) for ...